Merck AIDS studies
Executive Summary
L-697,639 reverse transcriptase inhibitor began early clinical studies (40 patients enrolled) during the second week of December. Studies are being conducted under auspices of NIAID. Based on the accelerated pace of research throughout the industry, Merck Chairman Vagelos has previously predicted that a major new product will enter the AIDS category within the next two years.